Vertex Pharmaceuticals Statistics

Total Valuation

Vertex Pharmaceuticals has a market cap or net worth of GBP 81.38 billion. The enterprise value is 73.86 billion.

Market Cap	81.38B
Enterprise Value	73.86B

Important Dates

The next estimated earnings date is Thursday, February 6, 2025.

Earnings Date	Feb 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.91%
Shares Change (QoQ)	+1.12%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	256.79M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	7.95
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.63, with an EV/FCF ratio of -89.52.

EV / Earnings	-206.31
EV / Sales	8.74
EV / EBITDA	20.63
EV / EBIT	21.91
EV / FCF	-89.52

Financial Position

The company has a current ratio of 2.47, with a Debt / Equity ratio of 0.11.

Current Ratio	2.47
Quick Ratio	2.08
Debt / Equity	0.11
Debt / EBITDA	0.39
Debt / FCF	-1.60
Interest Coverage	110.38

Financial Efficiency

Return on equity (ROE) is -2.99% and return on invested capital (ROIC) is 15.29%.

Return on Equity (ROE)	-2.99%
Return on Assets (ROA)	12.05%
Return on Capital (ROIC)	15.29%
Revenue Per Employee	1.47M
Profits Per Employee	-66,292
Employee Count	5,400
Asset Turnover	0.48
Inventory Turnover	5.58

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -1.03% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-1.03%
50-Day Moving Average	469.14
200-Day Moving Average	457.66
Relative Strength Index (RSI)	22.53
Average Volume (20 Days)	3,879

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.68

Income Statement

In the last 12 months, Vertex Pharmaceuticals had revenue of GBP 7.93 billion and -357.98 million in losses. Loss per share was -1.39.

Revenue	7.93B
Gross Profit	4.25B
Operating Income	3.16B
Pretax Income	193.69M
Net Income	-357.98M
EBITDA	3.32B
EBIT	3.16B
Loss Per Share	-1.39

Full Income Statement

Balance Sheet

The company has 4.87 billion in cash and 1.32 billion in debt, giving a net cash position of 7.05 billion.

Cash & Cash Equivalents	4.87B
Total Debt	1.32B
Net Cash	7.05B
Net Cash Per Share	n/a
Equity (Book Value)	11.66B
Book Value Per Share	45.25
Working Capital	4.35B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -628.66 million and capital expenditures -196.37 million, giving a free cash flow of -825.04 million.

Operating Cash Flow	-628.66M
Capital Expenditures	-196.37M
Free Cash Flow	-825.04M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 53.59%, with operating and profit margins of 39.89% and -4.52%.

Gross Margin	53.59%
Operating Margin	39.89%
Pretax Margin	2.44%
Profit Margin	-4.52%
EBITDA Margin	41.85%
EBIT Margin	39.89%
FCF Margin	n/a

Dividends & Yields

Vertex Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.91%
Shareholder Yield	0.91%
Earnings Yield	-0.44%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Vertex Pharmaceuticals has an Altman Z-Score of 11.97.

Altman Z-Score	11.97
Piotroski F-Score	n/a